JP2022508513A5 - - Google Patents
Info
- Publication number
- JP2022508513A5 JP2022508513A5 JP2021542070A JP2021542070A JP2022508513A5 JP 2022508513 A5 JP2022508513 A5 JP 2022508513A5 JP 2021542070 A JP2021542070 A JP 2021542070A JP 2021542070 A JP2021542070 A JP 2021542070A JP 2022508513 A5 JP2022508513 A5 JP 2022508513A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- compound
- administered
- pharmaceutically acceptable
- cocrystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739809P | 2018-10-01 | 2018-10-01 | |
| US62/739,809 | 2018-10-01 | ||
| US201862773980P | 2018-11-30 | 2018-11-30 | |
| US62/773,980 | 2018-11-30 | ||
| PCT/US2019/053721 WO2020072334A1 (en) | 2018-10-01 | 2019-09-30 | Combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022508513A JP2022508513A (ja) | 2022-01-19 |
| JP2022508513A5 true JP2022508513A5 (https=) | 2022-10-13 |
| JP7466549B2 JP7466549B2 (ja) | 2024-04-12 |
Family
ID=69945395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542070A Active JP7466549B2 (ja) | 2018-10-01 | 2019-09-30 | がん治療のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11529339B2 (https=) |
| EP (1) | EP3860610A4 (https=) |
| JP (1) | JP7466549B2 (https=) |
| KR (1) | KR20210069642A (https=) |
| CN (1) | CN112839658B (https=) |
| AU (1) | AU2019351811B2 (https=) |
| BR (1) | BR112021006318A2 (https=) |
| CA (1) | CA3114401A1 (https=) |
| IL (1) | IL281845B2 (https=) |
| MX (1) | MX2021003842A (https=) |
| SG (1) | SG11202103141YA (https=) |
| WO (1) | WO2020072334A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281845B2 (en) | 2018-10-01 | 2025-06-01 | Celgene Corp | Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma |
| WO2021113212A1 (en) * | 2019-12-02 | 2021-06-10 | Celgene Corporation | Therapy for the treatment of cancer |
| US20230255975A1 (en) * | 2020-06-25 | 2023-08-17 | Celgene Corporation | Methods for treating cancer with combination therapies |
| US20260098035A1 (en) | 2022-09-20 | 2026-04-09 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010082A (es) | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| KR20130038838A (ko) | 2010-03-12 | 2013-04-18 | 셀진 코포레이션 | 레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법 |
| PH12013501837A1 (en) | 2011-03-11 | 2013-11-18 | Celgene Corp | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
| ES2885769T3 (es) | 2012-08-09 | 2021-12-15 | Celgene Corp | Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona |
| US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| AU2013299627C1 (en) * | 2012-08-09 | 2018-05-31 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| CA3108974C (en) | 2012-08-09 | 2023-04-04 | Celgene Corporation | Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| LT2882441T (lt) | 2012-08-09 | 2020-07-27 | Celgene Corporation | Su imunitetu susijusių ir uždegiminių ligų gydymas |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| UA117141C2 (uk) * | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| AU2015305449B2 (en) * | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| IL281845B2 (en) | 2018-10-01 | 2025-06-01 | Celgene Corp | Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma |
| EA202190865A1 (ru) * | 2018-11-30 | 2021-07-01 | Селджин Корпорейшн | Комбинированная терапия для лечения рака |
-
2019
- 2019-09-30 IL IL281845A patent/IL281845B2/en unknown
- 2019-09-30 EP EP19869422.6A patent/EP3860610A4/en active Pending
- 2019-09-30 CA CA3114401A patent/CA3114401A1/en active Pending
- 2019-09-30 JP JP2021542070A patent/JP7466549B2/ja active Active
- 2019-09-30 CN CN201980065270.1A patent/CN112839658B/zh active Active
- 2019-09-30 AU AU2019351811A patent/AU2019351811B2/en active Active
- 2019-09-30 BR BR112021006318A patent/BR112021006318A2/pt unknown
- 2019-09-30 US US16/588,318 patent/US11529339B2/en active Active
- 2019-09-30 WO PCT/US2019/053721 patent/WO2020072334A1/en not_active Ceased
- 2019-09-30 MX MX2021003842A patent/MX2021003842A/es unknown
- 2019-09-30 KR KR1020217009735A patent/KR20210069642A/ko not_active Ceased
- 2019-09-30 SG SG11202103141YA patent/SG11202103141YA/en unknown
-
2022
- 2022-11-09 US US17/983,762 patent/US12605372B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508513A5 (https=) | ||
| US10632112B2 (en) | Combination therapy for treatment of HBV infections | |
| JP2022537551A5 (https=) | ||
| US12077554B2 (en) | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
| RU2717331C2 (ru) | Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени | |
| TWI633887B (zh) | 用於預防及／或治療多囊性腎臟病之藥物 | |
| JP2018531605A5 (https=) | ||
| JP2020523317A5 (https=) | ||
| RU2358730C2 (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2020515523A5 (https=) | ||
| JP7420888B2 (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| CN1181819C (zh) | 使用五氟苯磺酰胺的综合疗法 | |
| EP4349341A1 (en) | Pharmaceutical preparation for preventing or treating pulmonary fibrosis | |
| CN118946371A (zh) | 靶向psma的放射性药物和检查点抑制剂的组合疗法 | |
| US20220296557A1 (en) | Combinations of bcl-2/bcl-xl inhibitors and related uses | |
| CN1711090A (zh) | 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 | |
| JP2019038858A (ja) | ペマフィブラートを含有する医薬 | |
| JP2024505515A5 (https=) | ||
| TW201618777A (zh) | 脂質異常症治療劑 | |
| JP2016521760A5 (https=) | ||
| CN102869353A (zh) | 自身免疫疾病的治疗 | |
| JP2016210688A (ja) | 放射性抗腫瘍剤、及び、抗腫瘍用キット | |
| WO2021217084A1 (en) | Use of nitro-fatty acids and analogues thereof for the prevention and/or treatment of acute lung injury and/or sars-cov-2 infection | |
| RU2008111064A (ru) | Кристаллические формы дельта и ипсилон иматинибмезилата | |
| HK1225968B (en) | Combination therapy for treatment of hbv infections |